ALOPM.PA Oncodesign Precision Medicine
- Market cap
- EUR 4.58M
- P/E
- -
- P/B
- 1.17x
- ROE
- 10.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ALOPM.PA undervalued?
Graham numberThe Graham number of Oncodesign Precision Medicine cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oncodesign Precision Medicine fundamental analysis
No fundamental analysis for Oncodesign Precision Medicine yet.
Oncodesign Precision Medicine stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oncodesign Precision Medicine
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced…
Full company profileOncodesign Precision Medicine financial statements
Oncodesign Precision Medicine annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 4.41M | 3.83M | 7.98M | 1.07M | 207K | 261K |
| Gross Profit | -4.70M | -1.98M | 460K | -6.60M | -6.29M | 9.73M |
| Operating Income | -6.17M | -3.73M | -1.61M | -9.94M | -7.81M | 8.22M |
| EBITDA | - | - | -1.44M | -9.46M | -7.26M | 6.06M |
| Net Income | -154K | -2.94M | -231K | -8.09M | -7.21M | 5.48M |
| EPS | -0.02 | -0.43 | -0.01 | -0.49 | -0.40 | 0.30 |
| Balance Sheet | ||||||
| Total Assets | 12.4M | 8.37M | 18.4M | 16.6M | 10.7M | 15.0M |
| Total Liabilities | 5.44M | 4.17M | 6.59M | 12.9M | 11.1M | -37.9M |
| Shareholders' Equity | 6.97M | 4.20M | 11.8M | 3.69M | -429K | 52.9M |
| Cash & Short-term Investments | 8.43M | 4.92M | 13.4M | 323K | 437K | 312K |
| Cash Flow | ||||||
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Ratios | ||||||
| ROE | -2.2% | -70.1% | -2.0% | -219.2% | - | 10.4% |
| ROA | -1.2% | -35.2% | -1.3% | -48.6% | -67.3% | 36.6% |
| Net Profit Margin | -3.5% | -76.9% | -2.9% | -754.6% | -3,482.2% | 2,098.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Oncodesign Precision Medicine dividends
Oncodesign Precision Medicine has not paid dividends in the last 6 fiscal years.
Who owns Oncodesign Precision Medicine
- Insiders 57.11%
- Institutions 0.00%
- Public & others 42.89%
- Shares outstanding 19.1M
- Free float 17.4M
Oncodesign Precision Medicine company profile
- Company name
- Oncodesign Precision Medicine
- Ticker
- ALOPM.PA
- ISIN
- FR001400CM63
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- December
- Address
- 18 Rue Jean Mazen, Dijon, France, 21000
- Phone
- 33 310 451 820
- Website
- oncodesign.com
About Oncodesign Precision Medicine
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers under PROMETHE brand; Nanocyclix, a kinase inhibitors, as well as on developing treatment for pancreatic and other cancers. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.
Oncodesign Precision Medicine management
5- Dr. Philippe Genne Ph.D.Chairman & CEO
- Ms. Karine LignelChief Operating Officer · born 1970
- Dr. Jan Hoflack Ph.D.Chief Scientific Officer · born 1960
- Mr. Stephane GerartChief Information Officer · born 1983
- Sylvie Fernandes ForsterChief Legal Officer